Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults - AI444-330
Updated: 17 July, 2018 | ClinicalTrials.gov
Inclusion Criteria: 1. This study will include patients greater than or equal to 18 years of age with chronic Hepatitis C, all genotypes, including naïve and experimented (null or partial) responders, intolerant to interferon (IFN) with or without cirrhosis, HIV/HCV coinfection, and liver transplant recipients at the sentinel sites, who received at least 1 dose of daclatasvir for the treatment of chronic Hepatitis C during the specified 24-month study period. Exclusion Criteria: 1. Subjects who received daclatasvir as part of a clinical trial. 2. Subjects who received daclatasvir for any indication other than local approved. 3. Contraindications included in the approved Mexican prescribing information.